T. Takahashi

Gene expressions for thymidylate synthase (TS), orotate phosphoribosyltransferase (OPRT), and thymidine phosphorylase (TP), not dihydropyrimidine dehydrogenase (DPD), influence outcome of patients (pts) treated with S-1 for gastric cancer (GC).

W. Ichikawa, R. Hirayama, K. Suto, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)

T. Mok, Y. Ichinose, M. Maemondo, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

The effect of CYP 2 C 19 polymorphism on the safety , tolerability , and pharmacokinetics of tivantinib ( ARQ 197 ) : results from a phase I trial in advanced solid tumors

S. Akinaga, K. Muro, Y. Koh, 2013 .

Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer

M. Shimizu, W. Ichikawa, Z. Nihei, 2004, British Journal of Cancer.

Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer

W. Ichikawa, Z. Nihei, K. Sugihara, 2003, British Journal of Cancer.

SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 + panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results.

S. Noura, K. Oba, N. Minagawa, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Induction of y-glutamylcysteine synthetase gene expression by platinum drugs in peripheral mononuclear cells of lung cancer patients

O. Katoh, M. Yokozaki, M. Yamakido, 2005 .